L&S RESEARCH CORP.'s $1.45 MILLION SETTLEMENT WITH FTC
This article was originally published in The Tan Sheet
Executive Summary
L&S RESEARCH CORP.'s $1.45 MILLION SETTLEMENT WITH FTC over claims made for its Cybergenics product line includes a provision that the company will no longer promote chromium picolinate for fat-burning. The consent order requires L&S to "cease and desist from representing" that "chromium picolinate, in any [weight-loss] product or used in conjunction with any [weight-loss] program, builds muscle, reduces fat, or lowers cholesterol."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning